2. Search Result
Search Result
Results for "

CT26 colon carcinoma

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Oligonucleotides

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-176806
    Legubicin

    Doxorubicin-LNAA-Boc

    		 Drug Derivative Cancer
    Legubicin (Doxorubicin-LNAA-Boc) is a novel conjugate of Doxorubicin (HY-15142A) and a Legumain-cleavable peptide linker. Legubicin is activated by Legumain to release leucine-doxorubicin while sparing normal tissues. Legubicin inhibits tumor cell growth and reduces DNA binding in non-legumain expressing cells. Legubicin completely arrests tumor growth in mice bearing CT26 tumors. Legubicin can be used for the study of colon carcinoma (CRC) .
    Legubicin
  • HY-139716
    IMD-catechol

    		NF-κB Inflammation/Immunology
    IMD-catechol is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves efficacy in a CT26 mouse colon carcinoma tumor model while eliciting minimal adjuvant toxicity.
    IMD-catechol
  • HY-151506
    Phospholipid PL1

    		Liposome Cancer
    Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .
    Phospholipid PL1
  • HY-182759
    MN33-47

    		DNA Alkylator/Crosslinker Topoisomerase Caspase Bcl-2 Family Apoptosis Cancer
    MN33-47 is a multi-target anti-tumor compound with broad-spectrum anti-proliferative activity. MN33-47 relieves the inhibition of the mitochondrial apoptosis pathway by downregulating the anti-apoptotic protein Bcl-2, while activating caspase-3 and inhibiting Topoisomerase I activity, thereby promoting its degradation through the ubiquitin-proteasome and autophagy-lysosome pathways. MN33-47 can also induce DNA cross-linking and G2/M cell cycle arrest, inhibit cancer cell migration and activate the mitochondrial apoptosis pathway, thus exerting potent anti-tumor effects. MN33-47 can improve the water solubility of SN-38 (HY-13704), and exhibits dose-dependent tumor growth inhibition effects in CT26 tumor-bearing mouse models without obvious toxic and side effects. MN33-47 can be used in related studies on colorectal adenocarcinoma, cervical adenocarcinoma, hepatocellular carcinoma, alveolar basal epithelial adenocarcinoma, gastric cancer and colon cancer .
    MN33-47
  • HY-183513
    L-Ala-BPA

    		FAP Cancer
    L-Ala-BPA is a boron delivery agent. L-Ala-BPA is transported into tumor cells via PEPT1/2 and LAT-1 (SLC7A5) pathways and is rapidly cleaved systemically by endogenous proteases including FAP to yield L-BPA (HY-W087830). L-Ala-BPA shows antitumor activity and can be used for the research of Boron Neutron Capture Therapy (BNCT) .
    L-Ala-BPA
  • HY-183597
    L-BPA-BPA

    		Drug Derivative Cancer
    L-BPA-BPA is an aromatic dipeptide and an analog of L-BPA (HY-W087830). L-BPA-BPA undergoes rapid hydrolytic cleavage in vivo to release the boron neutron capture agent L-BPA. L-BPA-BPA enables boron delivery to tumors; when used in combination with neutron irradiation, it also induces immunological effects including vaccine responses and abscopal tumor suppression. L-BPA-BPA can be used in the research of colon cancer and hypopharyngeal cancer .
    L-BPA-BPA

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: